Cargando…

NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan

Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Shih-Lung, Sheu, Chau-Chyun, Chian, Chih-Feng, Hsu, Jeng-Yuan, Kao, Kuo-Chin, Hang, Liang-Wen, Lin, Ching-Hsiung, Fang, Wen-Feng, Wang, Hao-Chien, Perng, Diahn-Warng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598748/
https://www.ncbi.nlm.nih.gov/pubmed/36289624
http://dx.doi.org/10.3390/biomedicines10102362
_version_ 1784816427987894272
author Cheng, Shih-Lung
Sheu, Chau-Chyun
Chian, Chih-Feng
Hsu, Jeng-Yuan
Kao, Kuo-Chin
Hang, Liang-Wen
Lin, Ching-Hsiung
Fang, Wen-Feng
Wang, Hao-Chien
Perng, Diahn-Warng
author_facet Cheng, Shih-Lung
Sheu, Chau-Chyun
Chian, Chih-Feng
Hsu, Jeng-Yuan
Kao, Kuo-Chin
Hang, Liang-Wen
Lin, Ching-Hsiung
Fang, Wen-Feng
Wang, Hao-Chien
Perng, Diahn-Warng
author_sort Cheng, Shih-Lung
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 patients (aged 74.6 ± 9.1 years and 83.2% men) with IPF were collected over 2 years (2018−2020) from medical centers in Taiwan at baseline, 1 month, and subsequent 3-month intervals. Treated patients (n = 88) received the antifibrotics nintedanib or pirfenidone, compared with the untreated group (n = 13). The 2-year assessment revealed overall preserved lung functionality in the treated patients, with insignificant changes from baseline for percent predicted forced vital capacity or FVC (±1.7%). The presence of respiratory comorbidities significantly increased the risk of both AE and death (with or without AE) over the full study duration. Furthermore, the decline of predicted FVC significantly increased with the risk of acute exacerbations (AE) in the second year. Overall, antifibrotic medication was beneficial in stalling IPF progression, reducing AEs, and delaying mortality in the treated cohort, despite their lower baseline lung functions. Further, no new safety concerns over antifibrotic treatments were observed for the Taiwanese population.
format Online
Article
Text
id pubmed-9598748
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95987482022-10-27 NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan Cheng, Shih-Lung Sheu, Chau-Chyun Chian, Chih-Feng Hsu, Jeng-Yuan Kao, Kuo-Chin Hang, Liang-Wen Lin, Ching-Hsiung Fang, Wen-Feng Wang, Hao-Chien Perng, Diahn-Warng Biomedicines Article Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 patients (aged 74.6 ± 9.1 years and 83.2% men) with IPF were collected over 2 years (2018−2020) from medical centers in Taiwan at baseline, 1 month, and subsequent 3-month intervals. Treated patients (n = 88) received the antifibrotics nintedanib or pirfenidone, compared with the untreated group (n = 13). The 2-year assessment revealed overall preserved lung functionality in the treated patients, with insignificant changes from baseline for percent predicted forced vital capacity or FVC (±1.7%). The presence of respiratory comorbidities significantly increased the risk of both AE and death (with or without AE) over the full study duration. Furthermore, the decline of predicted FVC significantly increased with the risk of acute exacerbations (AE) in the second year. Overall, antifibrotic medication was beneficial in stalling IPF progression, reducing AEs, and delaying mortality in the treated cohort, despite their lower baseline lung functions. Further, no new safety concerns over antifibrotic treatments were observed for the Taiwanese population. MDPI 2022-09-22 /pmc/articles/PMC9598748/ /pubmed/36289624 http://dx.doi.org/10.3390/biomedicines10102362 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cheng, Shih-Lung
Sheu, Chau-Chyun
Chian, Chih-Feng
Hsu, Jeng-Yuan
Kao, Kuo-Chin
Hang, Liang-Wen
Lin, Ching-Hsiung
Fang, Wen-Feng
Wang, Hao-Chien
Perng, Diahn-Warng
NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
title NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
title_full NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
title_fullStr NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
title_full_unstemmed NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
title_short NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
title_sort nicefit—a prospective, non-interventional, and multicentric study for the management of idiopathic pulmonary fibrosis with antifibrotic therapy in taiwan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598748/
https://www.ncbi.nlm.nih.gov/pubmed/36289624
http://dx.doi.org/10.3390/biomedicines10102362
work_keys_str_mv AT chengshihlung nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan
AT sheuchauchyun nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan
AT chianchihfeng nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan
AT hsujengyuan nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan
AT kaokuochin nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan
AT hangliangwen nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan
AT linchinghsiung nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan
AT fangwenfeng nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan
AT wanghaochien nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan
AT perngdiahnwarng nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan